Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
DSCI's Cash to Debt is ranked higher than
91% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.07 vs. DSCI: No Debt )
DSCI' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: No Debt

Equity to Asset 0.91
DSCI's Equity to Asset is ranked higher than
96% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. DSCI: 0.91 )
DSCI' s 10-Year Equity to Asset Range
Min: 0.28   Max: 0.94
Current: 0.91

0.28
0.94
Interest Coverage No Debt
DSCI's Interest Coverage is ranked higher than
95% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.42 vs. DSCI: No Debt )
DSCI' s 10-Year Interest Coverage Range
Min: 0.3   Max: 9999.99
Current: No Debt

0.3
9999.99
F-Score: 3
Z-Score: 9.95
M-Score: -3.10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -43.70
DSCI's Operating margin (%) is ranked higher than
52% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. DSCI: -43.70 )
DSCI' s 10-Year Operating margin (%) Range
Min: -62.5   Max: 4.71
Current: -43.7

-62.5
4.71
Net-margin (%) -43.68
DSCI's Net-margin (%) is ranked higher than
52% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.99 vs. DSCI: -43.68 )
DSCI' s 10-Year Net-margin (%) Range
Min: -60   Max: 2.4
Current: -43.68

-60
2.4
ROE (%) -30.19
DSCI's ROE (%) is ranked higher than
55% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.72 vs. DSCI: -30.19 )
DSCI' s 10-Year ROE (%) Range
Min: -94.12   Max: 6.11
Current: -30.19

-94.12
6.11
ROA (%) -27.54
DSCI's ROA (%) is ranked higher than
54% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.08 vs. DSCI: -27.54 )
DSCI' s 10-Year ROA (%) Range
Min: -49.48   Max: 4.6
Current: -27.54

-49.48
4.6
ROC (Joel Greenblatt) (%) -166.83
DSCI's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. DSCI: -166.83 )
DSCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -156.25   Max: 17.26
Current: -166.83

-156.25
17.26
Revenue Growth (%) -19.40
DSCI's Revenue Growth (%) is ranked higher than
53% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. DSCI: -19.40 )
DSCI' s 10-Year Revenue Growth (%) Range
Min: -39.6   Max: 19.6
Current: -19.4

-39.6
19.6
EPS Growth (%) 53.10
DSCI's EPS Growth (%) is ranked higher than
95% of the 220 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. DSCI: 53.10 )
DSCI' s 10-Year EPS Growth (%) Range
Min: -29.7   Max: 122.4
Current: 53.1

-29.7
122.4
» DSCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

DSCI Guru Trades in Q4 2013

Chuck Royce 55,000 sh (New)
» More
Q1 2014

DSCI Guru Trades in Q1 2014

Jim Simons 95,281 sh (New)
Chuck Royce 55,000 sh (unchged)
» More
Q2 2014

DSCI Guru Trades in Q2 2014

Chuck Royce 55,000 sh (unchged)
Jim Simons Sold Out
» More
Q3 2014

DSCI Guru Trades in Q3 2014

Chuck Royce 55,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with DSCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.70
DSCI's P/B is ranked higher than
87% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.38 vs. DSCI: 1.70 )
DSCI' s 10-Year P/B Range
Min: 0.5   Max: 7.72
Current: 1.7

0.5
7.72
P/S 2.40
DSCI's P/S is ranked higher than
74% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.74 vs. DSCI: 2.40 )
DSCI' s 10-Year P/S Range
Min: 0.21   Max: 3.26
Current: 2.4

0.21
3.26
EV-to-EBIT -3.95
DSCI's EV-to-EBIT is ranked lower than
57% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.42 vs. DSCI: -3.95 )
DSCI' s 10-Year EV-to-EBIT Range
Min: -224.5   Max: 663.7
Current: -3.95

-224.5
663.7
Current Ratio 9.70
DSCI's Current Ratio is ranked higher than
96% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.72 vs. DSCI: 9.70 )
DSCI' s 10-Year Current Ratio Range
Min: 1.05   Max: 15.92
Current: 9.7

1.05
15.92
Quick Ratio 8.38
DSCI's Quick Ratio is ranked higher than
96% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. DSCI: 8.38 )
DSCI' s 10-Year Quick Ratio Range
Min: 0.4   Max: 13.56
Current: 8.38

0.4
13.56

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.15
DSCI's Price/Net Cash is ranked higher than
97% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. DSCI: 3.15 )
DSCI' s 10-Year Price/Net Cash Range
Min: 1.68   Max: 272
Current: 3.15

1.68
272
Price/Net Current Asset Value 2.66
DSCI's Price/Net Current Asset Value is ranked higher than
97% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. DSCI: 2.66 )
DSCI' s 10-Year Price/Net Current Asset Value Range
Min: 1.06   Max: 485
Current: 2.66

1.06
485
Price/Tangible Book 2.11
DSCI's Price/Tangible Book is ranked higher than
86% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.44 vs. DSCI: 2.11 )
DSCI' s 10-Year Price/Tangible Book Range
Min: 0.42   Max: 15.27
Current: 2.11

0.42
15.27
Price/DCF (Projected) 12.38
DSCI's Price/DCF (Projected) is ranked higher than
72% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.64 vs. DSCI: 12.38 )
DSCI' s 10-Year Price/DCF (Projected) Range
Min: 1.01   Max: 40
Current: 12.38

1.01
40
Price/Median PS Value 3.76
DSCI's Price/Median PS Value is ranked higher than
50% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.19 vs. DSCI: 3.76 )
DSCI' s 10-Year Price/Median PS Value Range
Min: 0.11   Max: 7.78
Current: 3.76

0.11
7.78
Earnings Yield (Greenblatt) -25.30
DSCI's Earnings Yield (Greenblatt) is ranked lower than
52% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.50 vs. DSCI: -25.30 )
DSCI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 8
Current: -25.3

0.2
8

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Derma Sciences Inc was incorporated on September 10, 1984. The Company is a tissue regeneration company engaged in three segments of the wound care marketplace: pharmaceutical wound care, advanced wound care and traditional wound care products. The Company has one drug candidate that initiated its Phase 3 study. The Company maintains manufacturing facilities in Toronto, Canada and Nantong, China and an established network of third party suppliers for its products. Its products are sold through distributors to health care providers such as wound care centers, extended care facilities, acute care facilities, home health care agencies and physicians' offices. Some of its products are sold through retail channels to care givers. The Company markets its products through direct sales representatives in the United States, Canada and the United Kingdom, and through independent distributors within other select international markets. In Pharmaceutical Wound Care, the DSC127 product is in clinical trial for the treatment of diabetic foot ulcers. The Phase 3 clinical trial for diabetic foot ulcers is expected to be completed by the end of 2015. In addition to the diabetic foot ulcer indication, the Company has begun preclinical testing for scar reduction. The product lines in Advanced Wound Care include MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB, BIOGUARD, and ALGICELL AG. The Traditional Wound Care line consists of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices. It also manufactures and market adhesive bandages and related first aid products for the medical, industrial, private label and retail markets. It markets a line of wound closure strips, nasal tube fasteners and a variety of catheter fasteners to doctors, clinics, nursing homes, hospitals and other institutions.
» More Articles for DSCI

Headlines

Articles On GuruFocus.com
Derma Sciences Inc. Reports Operating Results (10-Q) Nov 12 2010 
Derma Sciences Inc. Reports Operating Results (10-Q) May 12 2010 

More From Other Websites
New Consensus Guidelines and Practical Recommendations Published on the Optimal Use of Off-Loading... Dec 17 2014
Derma Sciences To Participate in Two Upcoming Investor Conferences in December Nov 25 2014
Derma Sciences To Participate in Two Upcoming Investor Conferences in December Nov 25 2014
DERMA SCIENCES, INC. Financials Nov 15 2014
Derma Sciences to Participate in Canaccord Genuity Medical Technologies and Diagnostics Forum Nov 14 2014
Derma Sciences Reports Third Quarter Financial Results Nov 10 2014
Derma Sciences posts 3Q loss Nov 10 2014
Derma Sciences posts 3Q loss Nov 10 2014
Derma Sciences Reports Third Quarter Financial Results Nov 10 2014
DERMA SCIENCES, INC. Files SEC form 10-Q, Quarterly Report Nov 07 2014
Is a Surprise Coming for Derma Sciences (DSCI) This Earnings Season? Nov 07 2014
Newly Published Final CMS Payments for 2015 Favorably Impact Derma Sciences’ TCC-EZ® and... Nov 06 2014
Newly Published Final CMS Payments for 2015 Favorably Impact Derma Sciences’ TCC-EZ® and... Nov 06 2014
Derma Sciences to Hold Third Quarter Financial Results Conference Call on November 10th Nov 04 2014
Derma Sciences to Hold Third Quarter Financial Results Conference Call on November 10th Nov 04 2014
Derma Sciences Presented Clinical Evidence And Data On Its Tissue Regeneration Products for Diabetic... Oct 23 2014
Derma Sciences Presented Clinical Evidence And Data On Its Tissue Regeneration Products for Diabetic... Oct 23 2014
Derma Sciences Showcases "Off-Loading Your Diabetic Foot Ulcer, An Actor's Story," a Patient Video... Oct 17 2014
Derma Sciences Showcases "Off-Loading Your Diabetic Foot Ulcer, An Actor's Story," a Patient Video... Oct 17 2014
Derma Sciences to Present at Canaccord Genuity 34th Annual Growth Conference on August 14 Aug 12 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK